The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines

Tetanus-diphtheria-acellular pertussis (Tdap) vaccination during pregnancy protects newborns from pertussis in the early months of life. Previous research indicated that Tdap vaccination during pregnancy may blunt <i>Bordetella pertussis</i> (<i>B. pertussis)</i>-specific antibody responses in infants following acellular (aP) and whole cell pertussis (wP) vaccination. However, the effect of preexisting antibodies on infants' responses to diphtheria toxoid (DT), tetanus toxoid (TT) and <i>B. pertussis</i> antigens is less well-understood. This study aims to quantify the effect of preexisting anti-DT, anti-TT, and <i>B. pertussis</i>-specific antibody levels from Tdap vaccination during pregnancy on infants' post-primary and post-booster responses to aP- and wP-containing vaccines. This retrospective analysis utilized data collected from a randomized controlled trial (NCT02408926) between 2015 and 2018. Pregnant women received Tdap vaccination between 27 and 36 weeks gestation. Their term infants were randomized to receive either a pentavalent DTwP-HB-Hib (wP) or a hexavalent DTaP-HB-Hib-IPV (aP) vaccine. Preexisting immunity was defined as the levels of anti-DT, anti-TT, anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), and anti-pertactin (PRN) IgG at month 2 (pre-vaccination). Blood samples were collected at birth, month 2, month 7 (following primary series vaccination at 2, 4, 6 months), month 18 (pre-booster), and month 19 (post booster). A total of 132 aP-vaccinated and 123 wP-vaccinated children completed this study. High levels of pre-vaccination antibody levels correlated with lower geometric mean ratios (GMRs) at post-primary and post-booster following wP- and aP-containing vaccination. This effect was observed consistently across all vaccine antigens following primary and booster doses. The clinical significance of this observation requires further investigation.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2025-10-22
DOI
https://doi.org/10.1080/21645515.2025.2575638
Citations
1
Primary Topic
Bacterial Infections and Vaccines
Type
article
Field-Weighted Citation Impact
1.18
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines

Stephen John Kerr, Yong Poovorawan, Kirsten Maertens, Nasamon Wanlapakorn et al.
1 citations
Human Vaccines & Immunotherapeutics
Bacterial Infections and Vaccines
1.18
article

The effect of preexisting antibodies from Tdap vaccination during pregnancy on infant antibody responses to the pertussis-containing vaccines

Stephen John Kerr, Yong Poovorawan, Kirsten Maertens, Nasamon Wanlapakorn, Chacriya Sereeyothin
article en
1 citations

Abstract

Tetanus-diphtheria-acellular pertussis (Tdap) vaccination during pregnancy protects newborns from pertussis in the early months of life. Previous research indicated that Tdap vaccination during pregnancy may blunt <i>Bordetella pertussis</i> (<i>B. pertussis)</i>-specific antibody responses in infants following acellular (aP) and whole cell pertussis (wP) vaccination. However, the effect of preexisting antibodies on infants' responses to diphtheria toxoid (DT), tetanus toxoid (TT) and <i>B. pertussis</i> antigens is less well-understood. This study aims to quantify the effect of preexisting anti-DT, anti-TT, and <i>B. pertussis</i>-specific antibody levels from Tdap vaccination during pregnancy on infants' post-primary and post-booster responses to aP- and wP-containing vaccines. This retrospective analysis utilized data collected from a randomized controlled trial (NCT02408926) between 2015 and 2018. Pregnant women received Tdap vaccination between 27 and 36 weeks gestation. Their term infants were randomized to receive either a pentavalent DTwP-HB-Hib (wP) or a hexavalent DTaP-HB-Hib-IPV (aP) vaccine. Preexisting immunity was defined as the levels of anti-DT, anti-TT, anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), and anti-pertactin (PRN) IgG at month 2 (pre-vaccination). Blood samples were collected at birth, month 2, month 7 (following primary series vaccination at 2, 4, 6 months), month 18 (pre-booster), and month 19 (post booster). A total of 132 aP-vaccinated and 123 wP-vaccinated children completed this study. High levels of pre-vaccination antibody levels correlated with lower geometric mean ratios (GMRs) at post-primary and post-booster following wP- and aP-containing vaccination. This effect was observed consistently across all vaccine antigens following primary and booster doses. The clinical significance of this observation requires further investigation.

Human Vaccines & ImmunotherapeuticsVol. 21(1)
University of Antwerp (BE), Chulalongkorn University (TH), UNSW Sydney (AU), The Royal College Of Anesthesiologists Of Thailand (TH), Office of the Royal Society
Openalex Percentile: Top 16%
Bacterial Infections and Vaccines
1.18
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.